1062-1063 / 2437
Immune checkpoint inhibition
“Bristol-Myers Squibb today announced that
CheckMate -143, a randomized Phase 3 clinical trial
evaluating the efficacy and safety of
Opdivo
(nivolumab) in patients with first recurrence of
glioblastoma multiforme (GBM), did not meet its
primary endpoint of improved overall survival over
bevacizumab monotherapy.”